These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 36607775)

  • 1. Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value.
    Xie Y; Wei Y; Li D; Pu J; Ding H; Zhang X
    J Cardiovasc Pharmacol; 2023 Jan; 81(1):4-14. PubMed ID: 36607775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
    Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.
    Suzuki Y; Kaneko H; Okada A; Itoh H; Matsuoka S; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Kamiya K; Matsunaga A; Ako J; Node K; Yasunaga H; Komuro I
    Cardiovasc Diabetol; 2022 May; 21(1):67. PubMed ID: 35585590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
    Xu B; Li S; Kang B; Zhou J
    Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
    Duan XY; Liu SY; Yin DG
    Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibition and heart failure-current concepts.
    Custodio JS; Duraes AR; Abreu M; Albuquerque Rocha N; Roever L
    Heart Fail Rev; 2018 May; 23(3):409-418. PubMed ID: 29704192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure.
    Ghosh RK; Ghosh GC; Gupta M; Bandyopadhyay D; Akhtar T; Deedwania P; Lavie CJ; Fonarow GC; Aneja A
    Am J Cardiol; 2019 Dec; 124(11):1790-1796. PubMed ID: 31627834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
    Packer M
    Cardiovasc Diabetol; 2019 Oct; 18(1):129. PubMed ID: 31585532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death?
    Mukhopadhyay P; Sanyal D; Chatterjee P; Pandit K; Ghosh S
    Endocr Pract; 2022 Aug; 28(8):795-801. PubMed ID: 35569736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods.
    Chen HB; Yang YL; Meng RS; Liu XW
    ESC Heart Fail; 2023 Apr; 10(2):1231-1241. PubMed ID: 36702979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.
    Salah HM; Verma S; Santos-Gallego CG; Bhatt AS; Vaduganathan M; Khan MS; Lopes RD; Al'Aref SJ; McGuire DK; Fudim M
    J Cardiovasc Transl Res; 2022 Oct; 15(5):944-956. PubMed ID: 35290593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes.
    Woo VC
    Can J Diabetes; 2020 Feb; 44(1):61-67. PubMed ID: 31839265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
    Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; de Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B
    Circulation; 2018 Jul; 138(5):458-468. PubMed ID: 29526832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.